Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Haematologica. 2014 Sep;99(9):e159-61. doi: 10.3324/haematol.2014.106740. Epub 2014 Jun 27.
No abstract available

Keywords: bendamustine; effective treatment; relapsed/refractory chronic lymphocytic leukemia.

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Bendamustine Hydrochloride
  • Drug Administration Schedule
  • Drug Combinations
  • Female
  • Humans
  • Injections, Intravenous
  • Injections, Subcutaneous
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Male
  • Middle Aged
  • Nitrogen Mustard Compounds / therapeutic use*
  • Recurrence
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Alkylating
  • Drug Combinations
  • Nitrogen Mustard Compounds
  • Alemtuzumab
  • Bendamustine Hydrochloride